![中国临床肿瘤学会(CSCO)恶性血液病诊疗指南·2020](https://wfqqreader-1252317822.image.myqcloud.com/cover/547/33145547/b_33145547.jpg)
上QQ阅读APP看书,第一时间看更新
2.5 治疗
2.5.1 诱导缓解治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image141.jpg?sign=1739502467-oHaugCv66WCiu8PWwapOESiZLKRyKEzy-0-33d683bb48e3c0c1f26e36d804057bd1)
所有急性髓系白血病患者,可以参加临床研究的情况下,均建议首选参加临床研究。在没有临床研究的情况下,可以参照下述建议进行治疗。本章节为年龄<60岁成人患者。
2.5.2 诱导治疗后检测
诱导治疗过程中,建议在骨髓抑制期(停化疗后第7~14天左右)、恢复期(停化疗后第21~28天左右)复查骨髓。根据骨髓抑制期、血象恢复期的骨髓情况进行治疗调整。
(1)标准剂量Ara-C诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image142.jpg?sign=1739502467-0VVE18BB1eLDVmNYGMc8IlESg6YUWTqN-0-e0fc3a79812645238aa2d304d8aa5821)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image143.jpg?sign=1739502467-qGxCQCEUnMVWE7sTgqG3yxKfB7dmFqPf-0-4a9c95d5301380667150c289793ccc87)
标准剂量Ara-C诱导后治疗监测(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image144.jpg?sign=1739502467-lEqQzNLWcJdtmTOBg4x7kHRpFIaTXOrz-0-12b7f51cee97c254e0dc2b7da8eed0b8)
(2)含中大剂量Ara-C方案的诱导后治疗监测
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image145.jpg?sign=1739502467-K28kA5gLcj8TsR8dq6WClDegsb3qw5y7-0-64da456920f6089104ceebe96cb04e0d)
2.5.3 AML完全缓解后治疗的选择
按遗传学预后危险度分组治疗
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image146.jpg?sign=1739502467-Bmo2YeZ8u4yiFUbebS75lb6fRSphstyB-0-7268667f720a3fe123fb0883b7908ecc)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image147.jpg?sign=1739502467-dz9ZVTU0CodjktKycF27zzajm61nqoEb-0-abe56959d4b9eee4d51a895845ff5f33)
按遗传学预后危险度分组治疗(续表)
![](https://epubservercos.yuewen.com/1ACD66/17735533106543206/epubprivate/OEBPS/Images/image148.jpg?sign=1739502467-BM3WzVggWe5CFZH9xfeCrjA5o4g85YHA-0-909ad184390cea3893d0ed3e7ee57a3a)